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ImmunoscreeningSarcoidosis is a granulomatous inﬂammatory disease, diagnosed through tissue biopsy of involved organs in the
absence of other causes such as tuberculosis (TB). No speciﬁc serologic test is available to diagnose and differen-
tiate sarcoidosis from TB. Using a high throughput method, we developed a T7 phage display cDNA library
derived from mRNA isolated from bronchoalveolar lavage (BAL) cells and leukocytes of sarcoidosis patients.
This complex cDNA library was biopanned to obtain 1152 potential sarcoidosis antigens and a microarray was
constructed to immunoscreen two different sets of sera from healthy controls and sarcoidosis. Meta-analysis
identiﬁed 259 discriminating sarcoidosis antigens, and multivariate analysis identiﬁed 32 antigens with a sensi-
tivity of 89% and a speciﬁcity of 83% to classify sarcoidosis from healthy controls. Additionally, interrogating the
samemicroarray platform with sera from subjects with TB, we identiﬁed 50 clones that distinguish between TB,
sarcoidosis and healthy controls. The top 10 sarcoidosis and TB speciﬁc clones were sequenced and homologies
were searched in the public database revealing unique epitopes andmimotopes in each group. Here, we show for
the ﬁrst time that immunoscreenings of a library derived from sarcoidosis tissue differentiates between sarcoid-
osis and tuberculosis antigens. These novel biomarkers can improve diagnosis of sarcoidosis and TB, andmay aid
to develop or evaluate a TB vaccine.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sarcoidosis is an inﬂammatory granulomatous disease of unknown
etiology affecting multiple organs, such as the lungs, skin, CNS, and
eyes (Costabel, 2001; Costabel and Hunninghake, 1999; Iannuzzi et al.,
2007; Hunninghake et al., 1999). Common features shared by patients
with sarcoidosis are the presence of non-caseating granuloma, a
lack of cutaneous reaction to tuberculin skin testing (PPD) and in-
creased local and circulating inﬂammatory cytokines (Costabel, 2001;
Costabel and Hunninghake, 1999; Iannuzzi et al., 2007). In addition,
there is evidence of abnormal immune function accompanied by
hypergammaglobulinemia (Iannuzzi et al., 2007). Sarcoidosis shares
striking clinical and pathological similarities with infectious granuloma-
tous diseases, especially Mycobacteria tuberculosis (MTB) (IannuzziDivision of Pulmonary, Critical
ol of Medicine, 3990 John R, 3
ti).
. This is an open access article underet al., 2007; Prince et al., 2003). Although there is mounting evidence
of the presence of nonviable bacterial components (including MTB
and Propionibacterium acnes) in sarcoidosis tissue (Gupta et al., 2007;
Chen et al., n.d.; Negi et al., 2012), all attempts to isolate viable MTB
or other microbial pathogens from sarcoidosis tissue have failed
(Hunninghake et al., 1999; Chen et al., 2008).
Intradermal injection of the Kveim–Siltzbach suspension (a granulo-
matous splenic tissue suspension) induces granuloma formation weeks
later in sarcoidosis patients suggesting presence of antigen(s) in granu-
loma tissue and host immunoreactivity to these antigens (Dubaniewicz,
2010; Hajizadeh et al., 2007; Hiramatsu et al., 2003; Fox et al., 1983;
Munro andMitchell, 1987; Siltzbach and Ehrlich, 1954). Several studies
using state-of-the-art technologies have attempted to identify sarcoido-
sis antigens or to identify theunderlying genetic and environmental fac-
tors (Hajizadeh et al., 2007; Chen andMoller, 2007; Zhang et al., 2013),
yet unifying environmental or genetic factors as initiators of this disease
have not been found (Hunninghake et al., 1999; Dubaniewicz, 2010;
Eishi et al., 2002; Oswald-Richter and Drake, 2010). These studies re-
ported a number ofmarkers or variations in gene expression signatures,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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matory or granulomatous diseases (Koth et al., 2011; Maertzdorf et al.,
2012). This is partly due to the fact that several inﬂammatory diseases
may respond to various antigens with activation of a similar tran-
scriptome and/or inﬂammatory gene expression proﬁles (Koth et al.,
2011; Maertzdorf et al., 2012).
Proteomics, genomics, transcriptomics, and high throughput tech-
nology clearly suggest that early immune reaction to diverse antigens
is highly prevalent in a large number of rheumatic, neoplastic, and in-
ﬂammatory diseases such as sarcoidosis (Koth et al., 2011; Maertzdorf
et al., 2012; Bons et al., 2007; Stone et al., 2013). Since non-caseating
granulomas, cutaneous anergy and hypergammaglobulinemia suggest
an immune dysfunction in this disease, we hypothesize that sarcoidosis
is triggered by a group of unknown antigens represented in the host im-
mune cells. To identify the elusive antigen(s), we developed a heterolo-
gous cDNA library derived from bronchoalveolar cell (BAL) samples and
total white blood cells (WBC) from sarcoidosis patients. We then com-
bined both sarcoid-derived libraries with cultured human monocytes
and embryonic lung ﬁbroblast cDNA libraries to build a complex
sarcoidosis library (CSL). Furthermore, we used antibody recognition
and random plaque selection during biopanning of the cDNA libraries
to minimize the confounding effects of autoantibodies unrelated to
sarcoidosis. This approach has been successfully applied in biomarker
discovery for the diagnosis of lung, head and neck and breast cancer
(Fernandez-Madrid et al., 2004; Fernandez-Madrid et al., 1999; Lin
et al., 2007). We tested whether this novel library represents relevant
antigens and can speciﬁcally be recognized by high IgG titers present
in sera of sarcoidosis subjects. The essential feature that distinguishes
our method from previous studies is that we used the exquisite power
of antibody recognition present in human sera to interrogate the poten-
tial antigens present in macrophages and monocytes.
The present study describes a novel approach to identify sarcoidosis
antigens and to detect serum antibodies on high-throughput arrays.
Sera from 3 cohorts (sarcoidosis, controls, and TB) were used for
immunoscreening. Using bioinformatic tools, we have identiﬁed a
large number of biomarkers with high sensitivity and speciﬁcity that
can discriminate among the sera of patients with sarcoidosis, healthy
controls andMTB. Using the integrative-analysis method that combines
results from two independent trials, we have identiﬁed clones that
signiﬁcantly differentiate sarcoidosis from controls. Similarly, we identi-
ﬁed clones that differentially react with TB sera and notwith sarcoidosis
or control sera. Furthermore, the top 10 discriminating antigens for TB
and sarcoidosis were sequenced and homologies were identiﬁed in a
public database. These data indicate that we have developed a unique
library enabling the detection of highly signiﬁcant antigens to discrimi-
nate between patients with sarcoidosis and tuberculosis.
2. Materials and Methods
2.1. Chemicals
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO)
unless speciﬁed otherwise. LeukoLOCK ﬁlters and RNAlater were
purchased from Life Technologies (Grand Island, NY). The RNeasy
Midi kit was obtained fromQiagen (Valencia, CA). The T7mousemono-
clonal antibody was purchased from Novagen (San Diego, CA). Alexa
Fluor 647 goat anti-human IgG and Alex Fluor goat anti-mouse IgG
antibodies were purchased from Life Technologies (Grand Island, NY).
2.2. Patient Selection
This studywas approved by the institutional review board atWayne
State University and the Detroit Medical Center. Patients were recruited
at the center for Sarcoidosis and Interstitial Lung Diseases (SILD), which
is a referral center for patients with sarcoidosis and other ILDs.
Three sources of patient derived materials have been used in thisstudy: A) a BAL cDNA library was derived from BAL cells obtained
during diagnostic bronchoscopy from newly diagnosed patients with
sarcoidosis (n = 20); B) a leukocyte cDNA library were developed
from a different cohort of sarcoidosis patients who were followed in
an outpatient setting with various stages of sarcoidosis (n = 36);
and C) sera collected from 3 groups: 1) healthy controls, whowere vol-
unteers recruited from the community; 2) subjects with biopsy con-
ﬁrmed sarcoidosis who were followed in an outpatient setting; and
3) sera from subjects with culture positive TB collected at the Detroit
Department of Health andWellness Promotion. Subjects were included
whohad a diagnosis of sarcoidosis as proven by tissue biopsy per guide-
lines (Costabel and Hunninghake, 1999) and have a negative PPD. TB
subjectswere includedwho had a positive TB culture andwereHIV neg-
ative. Subjectswere excluded,whowere positive forHIVorwere receiv-
ing high dose immune suppressive medication that was deﬁned as
prednisone more than 15 mg per day alone or in combination with
immune modulatory medications. Subjects who had positive PPD or
quantiferon test were excluded from the sarcoidosis group. All study
subjects signed a written informed consent.
2.3. Bronchoalveolar Lavage
BAL cells were obtained, after informed consent, during diagnostic
bronchoscopy from subjects with active sarcoidosis as previously
described (Rastogi et al., 2011). BAL cells were suspended in 500 μL of
RNAlater and stored at−80 °C.
2.4. Collection of Total Leukocytes from Sarcoidosis Subjects
Leukocytes from 36 sarcoid subjects were isolated fromwhole blood
using LeukoLOCK ﬁlters as previously described (Glatt et al., 2009).
2.5. Human Macrophage (EL-1) and Human Lung Embryonic Fibroblast
(MRC-5) Cell Cultures
Both cell lines were obtained from ATCC and cultured as per ATTC
recommendations. From each cell line 1–2 mg RNA was isolated to
construct the cDNA library.
2.6. Serum Collection
Using standardized phlebotomyprocedures blood sampleswere col-
lected and allowed to clot and then centrifuged at 2500 rpm for 10min.
Supernatants were stored at−80 °C.
2.7. Construction of T7 Phage Display cDNA Libraries
Total RNA was isolated using the RNeasy Midi kit (Qiagen, Valencia,
CA). Integrity of the RNA samples was assessed using the Agilent 2100
bioanalyzer. Total RNA, in the amount of 1–2 mg, was subjected to
two cycles of polyA puriﬁcation tominimize ribosomal RNA contamina-
tion as suggested by the manufacturer (Qiagen, Valencia, CA). The
construction of phage cDNA libraries was performed using Novagen's
Orient Express cDNA Synthesis (Random Primer System) and Cloning
system as per manufacturer's suggestions (EMD Biosciences-
Novagen). Each library was cloned using modiﬁed linkers that allow
us to distinguish the phage clones (Chatterjee et al., 2006). The number
of clones in each of the 4 libraries was titrated by plaque assay as per
manufacturer's instructions (EMD Biosciences-Novagen). Finally, the
same number of phages from each BAL, WBC, EL-1 and MRC5 library
were pooled to generate a complex sarcoid library (CSL).
2.8. Biopanning of T7 Phage Displayed cDNA Library with Human Sera
Differential biopanning for negative and positive selection was
performed using sera from healthy controls to remove the non-
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to manufacturer's suggestions (T7 Select System, TB178; EMD
Biosciences-Novagen). Protein G Plus-agarose beads (Santa Cruz
Biotechnology) were used for serum IgG immobilization. Four
rounds of biopannings were performed and the selected phage li-
braries were used for microarray immunoscreening. Each cycle of
biopanning consisted of passing the entire phage library through
protein G beads coated with IgG from pooled sera of healthy controls,
then passing through beads coated with IgGs from individual serum
of sarcoid subjects.
2.9. Microarray Construction and Immunoscreening
Informative phage clones were randomly picked and ampliﬁed after
several rounds of biopannings and their lysates were arrayed in quintu-
plicates onto nitrocellulose FAST slides (Grace Biolabs, OR) using the
ProSys 5510TL robot (Cartesian Technologies, CA). The nitrocellulose
slides were then blocked with a solution of 1% BSA in PBS for 1 h at
room temperature followed by another hour of incubation with serum
at a dilution of 1:300 in 1× PBS as primary antibodies, together with
mouse anti-T7 capsid antibody (0.15 μg/mL) and BL21 Escherichia coli
cell lysates (5 μg/mL). BL21 E. coli cell lysates were added to remove an-
tibodies speciﬁc to E. coli from the serum. The microarrays were then
washed three times at room temperature with a solution of PBS/0.1%
Tween20 for 4 min. Secondary antibodies consisted of goat anti-human
IgG Alexa Fluor 647 (red ﬂuorescent dye) 1 μg/mL and goat anti-mouse
IgG Alexa Fluor 532 (green ﬂuorescent dye) 0.05 μg/mL. After 1 h of in-
cubation in the dark, the microarrays were washed 3 times with a solu-
tion of PBS/0.1% Tween20 for 4min at room temperature, and 2 times in
PBS for 4 min at room temperature and then air dried.
2.10. Sequencing of Phage cDNA Clones
Individual phage clones were PCR ampliﬁed using T7 phage forward
primer 5′ GTTCTATCCGCAACGTTATGG 3′ and reverse primer 5′ GGAG
GAAAGTCGTTTTTTGGGG3′ and sequenced byGenwiz (South Plainﬁeld,
NJ), using T7 phage sequence primer TGCTAAGGACAACGTTATCGG.
2.11. Data Acquisition and Pre-processing
Following the immunoreaction, the microarrays were scanned in an
Axon Laboratories 4100 scanner (Palo Alto, CA) using 532 and 647 nm
lasers to produce a red (Alexa Fluor 647) and green (Alexa Fluor 532)
composite image. Using the ImaGene 6.0 (Biodiscovery) image analysis
software, the binding of each sarcoid speciﬁc peptide with IgGs in each
serum was then analyzed and expressed as a ratio of red-to-green
ﬂuorescent intensities. The microarray data were further read into the
R environment v2.3.0 (Team RDC, 2004) and processed by a sequence
of pre-processing, including background correction, omission of poor
quality spots and log2 transformations. Within array loess normaliza-
tion was performed for each spot and summarized by median of tripli-
cates and followed by between array quantile normalization.
2.12. Statistical Analysis
We performed microarray analysis using sera from sarcoid patients
and healthy controls in two independent sets of experiments. Technical
and biological sources of variationwere expected in the design of exper-
iment. As opposed to pooling all datasets, one powerful and robust
method is to integrate results from individual datasets. We expected
to obtain a higher conﬁdence list of markers than by using individual
datasets. To detect differentially expressed antigens between sarcoido-
sis samples and healthy controls, an integrative analysis of two datasets
was performed. Limma's empirical Bayes moderated t-test identiﬁed
fold-changes in expression of antigens that differed signiﬁcantly be-
tween sarcoidosis and controls for each dataset separately. Then anintegrative-analysis method, an adaptively-weighted method with
one-sided correction (AW-OC) (Li and Tseng, 2011), was performed to
combine the statistics from both datasets. The integrative method was
designed to test whether an antigen is consistently over- or under-
expressed in sarcoidosis subjects in both datasets. False discovery
rate (FDR) was estimated using the Benjamini–Hochberg method
(Benjamini and Hochberg, 1995).
To identify a panel of markers that classify sarcoidosis samples and
controls, we used a strategy of univariate marker selection followed
by multivariate modeling. The top antigens differentially expressed in
the two groups were selected using the above described AW-OC ap-
proach.We used the top genes that were consistently up- or down-reg-
ulated in both datasets. The top markers were then required by the
supervised classiﬁcation models to achieve the most sensitivity and
speciﬁcity in differentiating sarcoid and controls. The multivariate clas-
siﬁcationmodels chosen for this studywere K-nearest neighbors (KNN)
and support vector machine (SVM). The cross-validation techniquewas
used to prevent the overﬁtting of data analysis due to a large number of
antigens used to discriminate between sarcoid and control subjects. The
study was performed in two nested 10-fold cross-validation loops, an
inner loop to select the optimal number of antigens and an outer loop
to measure the optimized model performance with estimation of the
area under the receiver operating characteristic (AUROC) sensitivity
and speciﬁcity. The receiver operating characteristic curves were esti-
mated through 10-fold cross-validation. A moderated t-test was carried
out to identify the signiﬁcant clones between healthy controls, sarcoid-
osis and tuberculosis.
3. Results
3.1. Generation of cDNA Libraries Representative of Sarcoidosis Antigens
Both PBMCs and alveolarmacrophages (AMs)play an important role
in initiation of sarcoidosis granuloma (Rastogi et al., 2011). It has been
shown that extracts from sarcoidosis BAL cells and peripheral
blood monocytes (PBMCs) are able to initiate a Kveim-like reaction
(Siltzbach and Ehrlich, 1954; Holter et al., 1992). Therefore, we used
total BAL cells and WBCs from patients with biopsy proven sarcoidosis
to develop a cDNA antigen library. We used BAL cells and WBC as
sources of antigens in order to increase the diversity of sarcoidosis anti-
gens. To increase the chance of identifying sarcoidosis antigen(s), we
isolated RNA from BAL samples obtained from 20 patients with active
sarcoidosis to generate the BAL cDNA library. The patients' characteris-
tics are shown in Table 1 (left panel). The LeukoLock systemwas used to
isolate RNA from total WBC obtained from a different cohort of 36
sarcoidosis subjects to build theWBC cDNA library. The patients' charac-
teristics are shown in Table 1 (right panel). Two other sources of cDNA,
one from cultured human splenic monocytes (EL-1) and another
from lung embryonic ﬁbroblasts (MRC5) were used to generate two
additional libraries. These sources were added to increase the chance
of discovering potential sarcoidosis antigens. Each cDNA underwent
two cycles of PolyA selection to minimize ribosomal contamination.
These four libraries were developed as described in the Materials and
Methods section. Each library was cloned using modiﬁed linkers;
ECOR1/HindIII was used for BAL cDNA, ALA for WBC cDNA, LEU for
MARC5 cDNA and THR for EL1 cDNA (S1). The use of these linkers
enabled us to identify the original library for each antigen.
3.2. Differential Biopanning of Sarcoidosis Phage cDNA Display Libraries
The four phage cDNA display libraries (BAL, WBC, EL-1 and MARC5)
were combined to generate a complex sarcoidosis library (CSL). To iso-
late a large panel of antigens, differential biopanning of the T7 phage
cDNA display library was performed on the combined complex sarcoid
library. A negative biopanning selection was done using 10 pooled sera
from healthy controls to remove non-speciﬁc IgG, while 2 sarcoidosis
Table 1
Subject demographics, chest X-ray stages, and organ involvements.
BAL derived RNA Leukocyte derived RNA
Age (Mean ± SEM) 30 ± 8 Age (Mean ± SEM) 36 ± 11.2
BMI (Mean ± SEM) 27.7 ± 8.7 BMI (Mean ± SEM) 31 ± 5.4
Gender, N (%) Gender, N (%)
Male 7 (33) Male 12 (33)
Female 13 (67) Female 24 (67)
Race, N (%) Race, N (%)
African American 17 (87) African American 32 (88)
Caucasian 3 (13) Caucasian 4 (12)
CXR stage, N (%) CXR Stage, N (%)
1 2 (6) 1 1 (3)
2 14 (67) 2 13 (41)
3 4 (27) 3 12 (37)
4 0 4 6 (19)
Lung 18 Lung 33
Extrapulmonary 16 Extrapulmonary 31
Neuro-ophthalmologic 6 Neuro-ophthalmologic 11
Skin 6 Skin 13
Liver 2 Liver 4
Heart 1 Heart 2
Prednisone 1 Prednisone 3
IMD 0 IMD 14
Smoking Smoking
None 12 None 26
Age, BMI and disease duration values are presented asmeans and variability in SDor range
where indicated. N = number of patients and percent is shown in parentheses. IMD =
Immunomodulatory drugs.
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tained from a woman (P51) with systemic sarcoidosis who had uveitis
and another serum was collected from a male subject (P197) who had
active systemic sarcoidosis with renal involvement. Both patients had
pulmonary involvements. Each clone was derived either from P51 or
from P197. The titer of the complex library was assessed (Supplemental
Fig. 2A) and individual phage clones were ampliﬁed by PCR (Supple-
mental Fig. 2B).
3.3. High-throughput Protein Microarray Immunoreaction to Select
Sarcoidosis Speciﬁc Antigens
A total of 1152 potential antigens were randomly selected from the
two highly enriched pools of T7 phage cDNA libraries (Fig. 1). These an-
tigens were robotically spotted on nitrocellulose Fast slides and were
hybridized with sera of sarcoidosis patients or healthy controls. The
binding of each of the arrayed potential sarcoidosis-speciﬁc peptides
with antibodies in sera was quantiﬁed with Alexa Fluor 647 (red-ﬂuo-
rescent dye)-labeled goat anti-human antibody. The amount of phage
particles at each spot throughout the microarray was detected using a
mouse monoclonal antibody to the T7 capsid protein and quantiﬁed
using Alexa Fluor 532 (green-ﬂuorescent dye)-labeled goat anti-
mouse antibody (Fig. 1). To correct for any small variation in the amount
of antibodybinding in each spot thatmay be due to different amounts of
phage spotted on the microarray, the ratio of intensity of Alexa Fluor
647 over Alexa Fluor 532was calculated for each spot. Following immu-
noreaction, the microarray data were processed by a sequence of trans-
formations and then analyzed. The intra-assay reproducibility was
assessed by comparing the results among ﬁve replicates printed within
the same chip for each clone.
3.4. Selection of a Panel of Antigens and Estimation of Neural Network
Classiﬁer Performance in Sarcoidosis
A novel aspect of our work was the integration of data from two in-
dependent trials of printing allowing the development of two datasets
obtained from two independent cohorts of sarcoidosis patients andhealthy controls utilized for hybridization. To generate the ﬁrst dataset,
sera from 54 sarcoidosis subjects and 45 healthy controls were
immune-screened against 1152 sarcoidosis speciﬁc peptides. In the sec-
ond dataset, sera from 19 healthy controls and 61 sarcoidosis subjects
were immune-screened using the same platform of clones. Sera used
in both datasets for hybridization had not been previously used for
biopanning or selection of clones. Table 2 shows the clinical characteris-
tics of sarcoidosis and healthy control subjects. Within array loess nor-
malization was performed for each spot and summarized by median
of triplicates and followed by between array quantile normalization.
After preprocessing, 1101 antigens common in both datasets were
used for further analysis. Univariate andmultivariate analyseswere per-
formed. Limma's empirical Bayes moderated t-test was used to identify
fold-changes in expression of antigens that differed signiﬁcantly be-
tween sarcoidosis and controls for each dataset separately. Then both
datasets were combined using an integrative-analysis method, an
adaptively-weighted method with one-sided correction (AW-OC) (Li
and Tseng, 2011). Out of the 1101 potential antigens, 259 showed a
strong differentiation between sarcoidosis and healthy control subjects
with adjusted p value (q value) of b0.05 and FDR (false discovery rate)
of b0.05. Fig. 2A shows the heatmap of the 259 signiﬁcant antigens that
were differentially expressed in both datasets. Seventy eight markers
out of 259 were consistently over- or under-expressed in sarcoidosis
subjects. Fig. 2B shows the AUROC for this classiﬁer. KNN method per-
formed slightly better than SVM. Using the highly signiﬁcant 32 anti-
gens selected by AW-OC and KNN methods to classify sarcoidosis and
healthy controls (AW-OC + KNN), the area under the curve (AUROC)
was 0.78, with a sensitivity of 89% and a speciﬁcity of 83% estimated
after 10-fold cross-validation (Fig. 2B).3.5. Characterization of 10 Most Signiﬁcant Sarcoidosis Antigens
Based on the results of AW-OC integrative-analysis, we identiﬁed
the top 10 high performance antigens that predict sarcoidosis. To
further characterize the performance of each clone, we next calculat-
ed the AUROC, and sensitivity and speciﬁcity given the optimal cutoff
of the clones. Fig. 3 depicts the ROC curves for individual sarcoid an-
tigens and their adjusted p value (q value). As shown, each antigen
has a different speciﬁcity and sensitivity as well as ROC to predict
the presence of sarcoidosis. ROC for these antigens ranged from the
highest of 0.84 to the lowest of 0.7. Nine of 10 antigens were clearly
increased in sarcoidosis versus healthy controls. To further charac-
terize the identiﬁed antigens, we have sequenced these 10 highest
ranked clones. After obtaining the sequences of clones, the Expasy
program was used to translate the cDNA sequences to protein se-
quences. Protein blast using Blastn and tblastn algorithms of the
BLAST program were applied to identify the highest homology to
our identiﬁed proteins or peptides. Additionally, we compared
these results with corresponding nucleotide sequences using nucle-
otide blast. We also determined the predicted amino acid in frame
with phage T7 gene 10 capsid proteins. Five antigens (RNAPII,
SAMDHI, DNAJC1, TPT1 and SH3YL1) among the top 10 clones ﬁt the
deﬁnition of an epitope containing known gene products in the read-
ing frame of known genes (Wang et al., 2005). The other ﬁve
contained peptides coded by the inserted gene fragments leading
to out of frame peptides, which meets the deﬁnition of mimotopes
(Wang et al., 2005). Full length of proteins and genes of 10 sarcoido-
sis clones are shown in Supplementary Table 1. As sarcoidosis sera
reacted to these out of frame peptides, it is likely that these clones
represent sarcoidosis antigens produced as a result of altered read-
ing frames or alternative splicing. Interestingly, when a similar tech-
nique was applied to discovery of cancer antigens, numerous out of
frame peptides were discovered (Lin et al., 2007; Wang et al.,
2005). Table 3 shows the 10 most signiﬁcant sarcoidosis antigens,
gene names and q-values.
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Fig. 1. Schematic diagram of discovery of sarcoidosis antigens. The process of combining phage-display technology, protein microarray and bioinformatic tools to select a panel of novel
clones for the diagnosis of sarcoidosis. A cDNA library was constructed from a pool of total RNA isolated from 20 BAL samples and 36WBC samples from sarcoid patients, and then com-
binedwith RNA extracts from cultured humanmonocytes and human embryonic ﬁbroblasts. After digestion, the cDNA librarywas inserted into the T7 phage vector and packaged into T7
phages to generate a sarcoid cDNA–phage-display library. Several rounds of biopannings of the library were performed with pooled control sera for negative selection, and with sarcoid
sera for positive enrichments. After four rounds of biopanning, enriched sarcoid speciﬁc peptide clones were cultured onto LB agar plates. A total of 1152 single colonies, including positive
and negative clones, were randomly picked and propagated into 96-well plates. Phage–clone lysates were then printed robotically onto coated glass slides to create a sarcoid–phage–pro-
tein microarray. Cy5 (red ﬂuorescent dye)-labeled antihuman antibody was used to detect IgGs in human serum that were reactive to peptide clones, and a Cy3 (green ﬂuorescent dye)-
labeled antibody was used to detect the phage capsid protein in order to normalize for spotting. Thus, if a phage clone carries a peptide that is non-reactive to human IgG, the spot will
remain green suggesting an unreactive clone,whereas clones reactive to human IgG give raise to a red signal. A total of 115 sarcoid sera, 64 healthy control sera and 17 TB sera were tested
on the 1152 phage peptide microarray. Bioinformatically analyzed data identiﬁed 259 antigens with the highest level of differentiation between sarcoidosis and healthy controls.
Table 2
Patient characteristics.
Control subjects TB subjects
Age 29.7 ± 13.4 y 33 ± 7.4 23 ± 14
BMI 29 ± 10.4 28 ± 3.6 21 ± 7.9
Gender, N
Female 87 (75) 48 (75) 7 (42)
Male 28 (25) 16 (25) 10 (58)
Race, N
African American 107 (89) 44 (69) 6 (36)
Caucasian 8 (11) 20 (31) 11 (64)
CXR stage, N
0 3 (2) NA NA
1 18 (15) NA NA
2 49 (43) NA NA
3 45 (39) NA NA
Organ involvements,
Neuro-ophthalmologic 33 (28) NA –
Lung 109 (94) NA 17/17
Skin 50 (45) NA –
Multiorgan 70 (52) NA –
PPDa Negative NA –
TB cultureb Negative NA Positive
Some patients had multiple organ involvements.
NA = not applicable.
a PPD =Mantoux test (puriﬁed protein derivative).
b TB cultures obtained from BAL, tissue or sputum.
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Tuberculosis Patients
In view of the clinical and pathological similarities betweenMTB and
sarcoidosis, a most useful clinical antigen(s) should discriminate be-
tween these two conditions. To this end, using the antigens identiﬁed
by biopanning the CSL library, a microarray was constructed and then
this construct was interrogated with sera from 17 culture positive
MTB subjects. Using a moderate t-test and a q value of b0.05 in this sys-
tem, we identiﬁed 238 clones differentially expressed between TB and
healthy controls and 380 clones differentially expressed between TB
and sarcoidosis. Fig. 4 shows a Venn diagram depicting the overlap be-
tween 259 sarcoidosis markers, 238 TB vs. control and 380 TB vs. sar-
coidosis markers. Clearly, 47 clones differentiate both sarcoidosis and
TB from healthy controls, while 5 of them cannot differentiate sarcoido-
sis fromTB. From these clones, 164were found to be TB speciﬁc, and dif-
ferent from both healthy controls and sarcoidosis clones. Fig. 5 shows
the heatmap of 50 signiﬁcant clones differentially expressed in all
three groups. Similarly to the sarcoidosis antigens, we have analyzed
the speciﬁcity and sensitivity of TB clones to predict the presence of
TB (Table 4). Finally, we sequenced 10 TB antigens, and sequence
homologies were searched using the same algorithm as previously de-
scribed. Table 4 shows the 10 TB-speciﬁc antigens as compared to
healthy controls as well as sarcoidosis. After sequence analysis and
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Fig. 2.A)Heatmap generated by applyingmeta-analysis usingmicroarray analysis of 2 separate datasets derived from 115 sarcoidosis patients and 64 healthy controls. Data reﬂecting 259
antigens expressed signiﬁcantly differently between healthy controls and sarcoidosis subjects in immunoscreening using sera. The 259 antigens are further divided into three categories
according to the AW-OCmethod. I: 78 antigens are consistently over- or under-expressed in sarcoidosis in both datasets; II: 115 antigens are over- or under-expressed in sarcoidosis in the
second dataset only; III: 66 antigens are over- or under-expressed in sarcoidosis in the ﬁrst dataset only. B) Receiver operating characteristics (ROC) curve demonstrating the performance
of 32 classiﬁers to discriminate between healthy controls and sarcoidosis subjects.
346 H. Talwar et al. / EBioMedicine 2 (2015) 341–350homology search, we found one identical sequence between TB and sar-
coidosis clone. Although the identiﬁed clone's name was different:
P51_BP3_287 versus P51_BP3_174, and they performed differently in
sarcoidosis versus TB as indicated in q value (compare Tables 3 and 4).
However, using NCBI blast databases (mycobacterium toxoid and the
universal blast) on the same sequence, two different proteins could be
identiﬁed. Supplementary Table 2 shows the full length of protein and
genes of 10 TB antigens. Surprisingly, TB clones showmuch higher sen-
sitivity and speciﬁcity; similarly the AUROC was larger for the majority
of TB antigens (Table 4).
4. Discussion
Our work was inspired by the classic observation that the intrader-
mal injection of a suspension of granulomatous splenic tissue (Kveim–
Siltzbach test) induces granuloma formation weeks later in patients
with sarcoidosis, suggesting the presence of antigen(s) in granuloma
tissue and host immunoreactivity to those antigen(s) (Iannuzzi et al.,
2007; Hajizadeh et al., 2007; Hiramatsu et al., 2003; Dubaniewicz
et al., 2006). Kveim-like effects have also been observed using non-
viable BAL cell extracts or PBMCs derived from sarcoidosis subjects
(Munro and Mitchell, 1987; Siltzbach and Ehrlich, 1954; Holter et al.,
1992; Kataria and Holter, 1996). Several studies have attempted to
identify speciﬁc antigens that can discriminate sarcoidosis from healthy
subjects or from patients with other granulomatous diseases such as TB
(Hajizadeh et al., 2007; Chen and Moller, 2007). Most of these studies
used limited proteomics or genomics to search for tissue antigens
(Hajizadeh et al., 2007; Richter et al., 1999; Song et al., 2005).
We tested the hypothesis that antigen presenting cells, especially AMs
might harbor elusive sarcoidosis antigen (s) in their phagosomes. By ap-
plying novel high throughput technology, here, we attempted to over-
come the current gap by constructing phage–protein microarrays in
which peptides derived from a unique sarcoidosis cDNA library were
expressed as a phage fusion protein. The phage–protein microarrayswere screened to identify phage–peptide clones that bind antibodies in
serum samples from patients with sarcoidosis but not in those from con-
trols. Importantly, we immune-screened the same microarray constructs
using sera of culture positive TB patients.
The average length of identiﬁed peptides for sarcoidosis antigens
was between 9 and 130 amino acids (AA), while the average peptide
length for TB antigens was 9–209 AA. Among 10 sarcoidosis speciﬁc
phage peptides, we identiﬁed 5 expression sequence tags with in
frame epitopes. Five other reactive antigens were relatively short out
of frame peptides meeting the criteria to be considered as mimotopes
(mimetic sequence of a true epitope) (Wang et al., 2005). Similarly,
among 10 sequenced TB speciﬁc phage peptides, we identiﬁed 5 in
frame epitopes with full length in frame proteins with homology to
known human sequences. Five other sequences were relatively short
peptides with homology to various known MTB proteins (Table 4). In-
terestingly, TB antigens had much higher speciﬁcity and sensitivity as
compared to antigens selective to sarcoidosis as indicated by higher
AUCs (Table 4). Although the signiﬁcance of mimotopes is not clear, it
has been shown that some out of frame peptides are immunogenic
and can activate MHC class I molecules (Schirmbeck et al., 2005). Due
to smaller peptide sequences of mimotopes, they may have homology
with diverse proteins. Prior studies using similar techniques in various
cancers had similarly identiﬁed out of frame peptides (Lin et al., 2007;
Chatterjee et al., 2006; Wang et al., 2005). Detection of mimotopes in
this method may be due to out of frame peptide synthesis secondary
to altered ribosomal function, or may correspond to open reading
frames or generation of displayed peptides due to competition for bind-
ing during phage selection during phage insertion.
Although our primary goal in this study was to identify the immune
signature in sarcoidosis, we have identiﬁed a panel of antigens differen-
tially expressed in sarcoidosis and tuberculosis as compared to healthy
subjects. Tables 3 and 4 summarize the 10 most signiﬁcant clones we
identiﬁed in sarcoidosis and tuberculosis respectively. Further studies
with larger sample sizes need to verify current data.
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Fig. 3. ROC for top 10 sarcoidosis clones.
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Table 3
Top 10 most signiﬁcant sarcoidosis clones, clone name, gene names, adjusted p values (q-values), AUC, sensitivity and speciﬁcity, conﬁdence interval (CI).
Clone Increased in sarcoidosis vs healthy controls Gene
name
q value AUC Sensitivity %, 95% CI Speciﬁcity %, 95% CI
P51_BP3_287 (MRC5) Small inducible cytokine A21 precursor CCL21 1.9 × 10−20 0.84 78 82
P51_BP3_281 (BAL) Methionine aminopeptidase 1 Metap 1 1.0 × 10−20 0.78 70 82
P51_BP4_388 (EL-1) Activated RNA polymerase II transcription cofactor variant 4 RNAP II 0.00045 0.75 70 74
P51_BP4_596 (WBC) RNA methyltransferase CLI_3190 0.00045 0.72 72 74
P51_BP4_566 (WBC) Tumor necrosis factor receptor superfamily member 21 precursor.
Also known as death receptor 6 (DR6)
TNFRSF21 0.0009 0.74 70 71
P51_BP3_283 (WBC) Monocyte differentiation antigen CD14 CD14 0.0009 0.74 68 65
P51_BP3_47 (EL-1) DnaJ (Hsp40) homologue subfamily C member 1 precursor DNAJC1 0.002 0.72 60 82
P197_BP4_885 (BAL) Amyloid β A4 precursor protein-binding family B member
1-interacting protein
APBB1 0.007 0.79 75 82
P51_BP4_577 (BAL) Fibroblast growth factor binding protein 2 precursor FGFBP-2 0.009 0.70 64 68
Clone Decreased in sarcoidosis vs healthy controls
P197_BP4_755 (BAL) SH3 domain-containing YSC84 like protein 1 SH3YL1 1.0 × 10−20 0.77 65 82
348 H. Talwar et al. / EBioMedicine 2 (2015) 341–350In recent years several groups have attempted to identify speciﬁc
signatures to distinguish between tuberculosis and sarcoidosis using
transcriptomics or gene expression proﬁlings (Koth et al., 2011;
Maertzdorf et al., 2012; Berry et al., 2010). Yet, most of these methods
led to the discovery of a series of markers or expression signatures
that failed to discriminate between these two diseases (Koth et al.,
2011; Stone et al., 2013). This is partly due to the fact that several in-
ﬂammatory or infectious diseases such as CD, lupus, sarcoidosis and tu-
berculosis may respond to various antigens with activation of similar
pathways leading to similar transcriptomes and/or inﬂammatory gene
expression proﬁles (Koth et al., 2011; Maertzdorf et al., 2012; Berry
et al., 2010). For instance, Maertzdorf et al. found more similarity in
the activated pathways than differences between sarcoidosis and MTB
(Maertzdorf et al., 2012). Their results in sarcoidosis were similar to
those results by Berry et al. indicating the importance of the interferon
pathway (IFN) signature in MTB (Maertzdorf et al., 2012; Berry et al.,
2010). In addition, considerable pathway overlap was identiﬁed be-
tween lupus, sarcoidosis and TB (Maertzdorf et al., 2012). However, de-
spite similar genetic or transcriptomic signatures, these diseases are
clinically entirely different and require different therapy. Tuberculosis,
a global infectious disease caused by the intracellular bacterium
Mycobacterium tuberculosis remains a worldwide health problemControls
Sarcoidosis MTB
MTB vs. Sarcoidosis
Fig. 4. Venn diagram depicts differential phage clone signiﬁcances among sarcoidosis, TB
and healthy controls (q b 0.01). Venn diagram shows the overlap between 259 sarcoidosis
clones and 238 TB clones as compared to healthy controls, as well as 380 TB clones versus
sarcoidosis. Forty seven clones could differentiate both sarcoidosis and TB from healthy
controls. Five clones could not discriminate between TB and sarcoidosis.(http://www.who.int). One barrier for eradication of tuberculosis be-
sides the lack of effective vaccination is the lack of reliable antigens to
evaluate the activity of the disease and its response to treatment
(Nahid et al., 2011). Standard methods to diagnose TB and to monitor
response to treatment rely on sputummicroscopy and culture. The cur-
rent CDC/NIH roadmap emphasizes the need for development of new
TB antigens as alternative methods (Nahid et al., 2011). In view of this
background, perhaps surprisingly, our microarray platform could dis-
criminate tuberculosis from sarcoidosis and healthy controls. In addi-
tion to antigens for sarcoidosis, we have detected more than 300
clones speciﬁcally for tuberculosis. Interestingly, a considerable number
of these clones were TB speciﬁc and related to bacterial growth of
M. tuberculosis, and its metabolism (Table 4). Recently a tremendous ef-
fort has been put toward elucidating the antibody response to MTB an-
tigens, which has implications for the development of new antigens to
diagnose and monitor successful treatment, as well as to develop effec-
tive vaccination (Kunnath-Velayudhan et al., 2010). Yet, a consistent
immune response to MTB has not been found. Most other studies
searching for antigens in TB have identiﬁed unspeciﬁc markers primar-
ily involving host response such as C-reactive protein, serum amyloid A
and others, but not MTB speciﬁc antigens (Agranoff et al., 2006; De
Groote et al., 2013). MTB has the ability to survive within host macro-
phages, largely escaping immune surveillance and maintaining its abil-
ity for replication and person to person transmission (Meena and Rajni,
2010). The primary goal of our project was to discover antigens related
to sarcoidosis. Yet, in additionwe have detected speciﬁc antigens for TB.
These results are surprising to us, as the question remains, how can the
sarcoidosis library detect TB speciﬁc antigens? Lungs are environmen-
tally highly exposed to numerous bacteria, and our library is predomi-
nantly derived from BAL cells that contain all types of immune cells,
including macrophages that might have integrated messages from
MTB. Hence, we speculate that this could be the reason why the CSL is
able to detect TB speciﬁc antigens. Still, the major question is why BAL
cells of patients with sarcoidosis can harborMTBmessages, yet respond
to PPD skin testing negatively, since all of our donors with sarcoidosis
were PPD negative.
Similar to gene-expression proﬁling and the pattern-recognition ap-
proaches utilizing serum proteomics, our method may have the limita-
tions of background signals, and sample-selection bias. To minimize
these problems, we have applied an integrative-analysis method, an
adaptively-weighted statistical method on two sets of data acquired in
two independent experiments. The discriminatory power of antibody
signatures was validated by analyzing data from two completely differ-
ent cohorts of patients.
In summary, we have developed a novel T7 phage display library de-
rived frommacrophages from BAL,monocytes from blood leukocytes of
patients with sarcoidosis that may display a signiﬁcant segment of the
SarcoidosisControls MTB
Color Key
Fig. 5. Heatmap generated from the microarray analysis using 3 datasets derived from 115 sarcoidosis patients, 64 control subjects and 17 TB patients. Fifty antigens showed signiﬁcant
differential expression among the three groups.
349H. Talwar et al. / EBioMedicine 2 (2015) 341–350universe of potential sarcoidosis andMTB antigens that can be specially
recognized by high IgG antibodies in sarcoidosis and MTB sera. Our re-
sults support the hypothesis that sarcoidosis sera can recognize anti-
gens presented in sarcoidosis materials. Current study of the antibody
response can advance howproteomics can be used to harness immunity
to identify and treat diseases, because it investigates antibody–antigen
interactions and also evaluates the effects on antibody responses of
pathogen and host characteristics. Further studies with a larger cohort
group of patients and/or longitudinal studies are needed to investigate
the role of these antigens in sarcoidosis and its organ involvement.Table 4
Top 10 most signiﬁcant tuberculosis clones, clone name, gene names, adjusted p values (q-val
Clone Increased in TB vs sarcoidosis subjects
P51_BP3_174 (MRC5) Ferredoxin (Mycobacterium tuberculosis)
P51_BP4_610 (BAL) WDFY3 protein (Homo sapiens)
P51_BP3_266 (EL-1) Membrane protein (Mycobacterium tuberculosis)
P51_BP3-166 (BAL) Leucine rich PPR-motif containing protein (Homo sapiens)
P51_BP4_704 (BAL) HLA-DR alpha (Homo sapiens)
P197_BP4_763 (BAL) Transketolase (Mycobacterium tuberculosis)
P51-BP4_563 (BAL) Dihydroxy acid dehydratase (Mycobacterium tuberculosis)
Clone Decreased in TB vs sarcoidosis subjects
P51_BP3_113 (BAL) Chain AMycobacterium tuberculosis
P51_BP3_200 (BAL) Disabled homologue 2 isoform 2 (Homo sapiens)
P51_BP4_622 (BAL) Transcription elongation factor B polypeptide 2 isoform (Homo saContributors
Harvinder Talwar contributed to the study design, sample process-
ing, conducted the analysis, and interpreted the data. Rita Rosati devel-
oped the T7 phage library and participated in the study design. Jia Li
contributed to data preprocessing and statistical analysis. Dana Kissner
provided access to patients with TB. Samiran Ghosh contributed to
data processing and statistical analysis. Félix Fernández-Madrid contrib-
uted to study design and data analysis. Lobelia Samavati conceived and
designed the study, participated in all areas of the research such asues), AUC, sensitivity and speciﬁcity, conﬁdence interval (CI).
Gene name q value AUC Sensitivity %, 95% CI Speciﬁcity %, 95% CI
Fed A 4.9 × 10−15 0.87 88 83
WDFY3 4.1 × 10−12 0.92 88 84
MFS 6.7 × 10−10 0.9 82 93
LRPPRC 1.3 × 10−9 0.81 71 90
HLA-DR 1.1 × 10−8 0.89 94 83
TKT 2.7 × 10−6 0.86 82 76
Rv0189C 1.04 × 10−6 0.85 76 86
BfrA 1.2 × 10−10 0.9 88 85
DAB2 1.5 × 10−9 0.92 82 91
piens) TCEB2 6.9 × 10−7 0.89 82 89
350 H. Talwar et al. / EBioMedicine 2 (2015) 341–350patient selection and oversaw patient enrollment, data analysis and
writing of the manuscript.
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